Results 181 to 190 of about 802,486 (287)

Harnessing Viral Proteases for Cellular and Molecular Engineering

open access: yesChemistry–Methods, EarlyView.
Engineered viral proteases (VIPs) provide programmable control of protein function with high specificity and low toxicity. Integrated with chemogenetic and optogenetic modules, these VIP systems enable logic gate manipulation for targeted regulation of cell signaling, gene expression, protein secretion, and degradation, thereby offering versatile ...
Mingguang Cui   +2 more
wiley   +1 more source

Wnt/β-Catenin Signaling Regulates Hepatitis B Virus cccDNA Levels. [PDF]

open access: yesInt J Mol Sci
Ishida A   +16 more
europepmc   +1 more source

A serum exosomal microRNA‐based artificial intelligence diagnostic model for highly accurate detection of hepatocellular carcinoma

open access: yes
Cancer Communications, EarlyView.
Jin‐Seong Hwang   +21 more
wiley   +1 more source

Pharmacokinetics, Safety, and Skin Irritation and Sensitization Potential of Clascoterone Cream in Early‐Phase Clinical Study Participants

open access: yesClinical Pharmacology in Drug Development, EarlyView.
Abstract Clascoterone is an androgen receptor inhibitor approved for the treatment of acne vulgaris in patients 12 years of age and older. Here, we report results of 5 phase 1 studies that assessed the pharmacokinetics (PK), safety, and skin irritation and sensitization potential of clascoterone cream 1% in healthy participants and patients with acne ...
Andrea Francesco Daniele Di Stefano   +8 more
wiley   +1 more source

Origins and Evolution of Hepatitis B Virus and Hepatitis D Virus.

open access: yesCold Spring Harbor Perspectives in Medicine, 2016
M. Littlejohn, S. Locarnini, L. Yuen
semanticscholar   +1 more source

Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Food Effect of Bexicaserin in Healthy Participants: A First‐in‐Human Randomized, Double‐Blind, Placebo‐Controlled Single Ascending Dose Escalation Phase 1 Study

open access: yesClinical Pharmacology in Drug Development, EarlyView.
Abstract Bexicaserin (LP352) is a selective 5‐hydroxytryptamine 2C (5‐HT2C) superagonist in development for the treatment of seizures in developmental and epileptic encephalopathies (DEEs). This double‐blind, placebo‐controlled, single ascending dose (SAD) Phase 1 study aimed to assess the safety, tolerability, and pharmacokinetic (PK) and ...
Rosa Chan   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy